Global Omics-Based Clinical Trials Market Size study, by Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies), By Indication (Oncology, Cardiology, Respiratory Diseases, S

Global Omics-Based Clinical Trials Market Size study, by Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies), By Indication (Oncology, Cardiology, Respiratory Diseases, Skin Diseases, CNS Diseases, Immunology, Genetic Diseases (includes the rare diseases), Others (includes ophthalmic, ear diseases)) and Regional Forecasts 2022-2028

Global Omics-Based Clinical Trials Market is valued at approximately USD 24.4 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 7.4 % over the forecast period 2022-2028. Omics-Based Clinical Trials are used for the clinical analysis of patients related to genomics, metabolomics epigenomics, proteomics etc. The growing incidences of chronic diseases have led to the adoption of Omics-Based Clinical Trials across the forecast period. For Instance: According to the Centers for Disease Control and Prevention in 2021, the number of cases and deaths by chronic diseases is increasing rapidly. The diabetic cases with illness have affected 285 million people which is equivalent to about 6.4 % of the total adult population globally. Increasing investment by pharmaceutical companies pushes the market growth of omics-based clinical trials. Also, with the increasing demand for omics approaches for clinical trials, the adoption & demand for Omics-Based Clinical Trials is likely to increase the market growth during the forecast period. However, higher costs of clinical trials impede the growth of the market over the forecast period of 2022-2028.

The geographical regions considered for the global Omics-Based Clinical Trials market analysis include Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world in terms of huge market share due to the increasing cases of chronic disorders, presence of key players and growing investment towards the advancement of healthcare. Whereas, Asia-Pacific is also estimated to attain a maximum growth rate during 2022-2028. Factors such as increasing R&D in clinical trials and increasing government expenditure towards the healthcare sector would create beneficial growth forecasts for the Omics-Based Clinical Trials market across Asia-Pacific region.

Major market players included in this report are:
Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer Inc.
Covance Inc.
Novo Nordisk
Rebus Bio

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Phase:
Phase I
Phase II
Phase III
Phase IV
By Study Design:
Interventional Studies
Observational Studies
Expanded Access Studies
By Indication:
Oncology
Cardiology
Respiratory Diseases
Skin Diseases
CNS Diseases
Immunology
Genetic Diseases (includes the rare diseases)
Others (includes ophthalmic, ear diseases, etc)
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019,2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Omics-Based Clinical Trials Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer Inc.
Covance Inc.
Novo Nordisk
Rebus Bio